Antares Pharma to Present at the 28th Annual Piper Jaffray Healthcare Conference
November 23 2016 - 7:00AM
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert F.
Apple, President and Chief Executive Officer, will present at the
28th Annual Piper Jaffray Healthcare Conference on Wednesday
November 30, 2016 at 3:30 pm, Eastern Time.
A live webcast of the presentation will be
available via the webcast tab under the Investor Information page
of the Antares website, www.antarespharma.com. A replay of the
webcast will also be archived on Antares’ website for 90 days
following the presentation.
About Antares Pharma
Antares Pharma focuses on self-administered
parenteral pharmaceutical products. The Company’s product, OTREXUP®
(methotrexate) injection for subcutaneous use, is approved in the
U.S. for the treatment of adults with severe active rheumatoid
arthritis, children with active polyarticular juvenile idiopathic
arthritis and adults with severe recalcitrant psoriasis. The
Company and Teva Pharmaceutical Industries, Ltd. (Teva) recently
announced the third quarter 2016 U.S. commercial launch of VIBEX®
Sumatriptan Injection USP for the acute treatment of migraine and
cluster headache. Antares Pharma is also developing
QuickShot® Testosterone for testosterone replacement therapy. The
Company's technology platforms include VIBEX® disposable auto
injectors, disposable multi-use pen injectors and reusable
needle-free injectors. Antares Pharma has a multi-product deal with
Teva that includes VIBEX® epinephrine, exenatide multi-dose pen,
and teriparatide multi-dose pen. Our reusable needle-free
injector for use with human growth hormone (hGH) is sold worldwide
by Ferring B.V. The Company is also working with AMAG
Pharmaceuticals on a subcutaneous method of administering Makena, a
progesterone product indicated for use in lowering the risk of
pre-term birth. For more information, visit
www.antarespharma.com.
SAFE HARBOR STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are subject to certain risks
and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such
differences include, but are not limited to: the results of the
phase 3 studies for QuickShot® Testosterone (QST) and acceptance of
the data by the U.S. Food and Drug Administration (“FDA”); the
timing and Company’s ability to successfully complete a New Drug
Application (“NDA”) for QST, acceptance of the NDA for QST by
the FDA and approval of the same by the FDA; Teva’s ability to
adequately and timely respond to the Complete Response Letter
received from the FDA for the VIBEX® epinephrine pen ANDA and
approval by the FDA of the same, the timing and therapeutic
equivalence rating thereof, and any future purchase orders and
revenue pre or post FDA approval; Teva’s ability to successfully
commercialize VIBEX® Sumatriptan Injection USP and the amount of
revenue from the same; FDA action with respect to Teva’s
Abbreviated New Drug Application (“ANDA”) filed for the Exenatide
pen and future revenue from the same; the outcome of the pending
patent litigation between Teva Pharmaceutical Industries, Ltd.
(Teva) and Eli Lilly and Company regarding the Teriparatide
multi-dose pen; FDA action with respect to Teva’s ANDA for the
Teriparatide multi-dose pen and the timing and approval, if any, by
the FDA of the same; continued growth of prescriptions and sales of
OTREXUP®; the timing and results of the development project
with AMAG Pharmaceuticals for an auto injector for Makena; the
timing and results of research projects, clinical trials, and
product candidates in development; actions by the FDA or other
regulatory agencies with the respect to the Company’s products or
product candidates of its partners; continued growth in product,
development, licensing and royalty revenue; the Company’s ability
to obtain financial and other resources for its research,
development, clinical, and commercial activities and other
statements regarding matters that are not historical facts, and
involve predictions. These statements involve known and unknown
risks, uncertainties and other factors that may cause actual
results, performance, achievements or prospects to be materially
different from any future results, performance, achievements or
prospects expressed in or implied by such forward-looking
statements. In some cases you can identify forward-looking
statements by terminology such as ''may'', ''will'', ''should'',
''would'', ''expect'', ''intend'', ''plan'', ''anticipate'',
''believe'', ''estimate'', ''predict'', ''potential'', ''seem'',
''seek'', ''future'', ''continue'', or ''appear'' or the negative
of these terms or similar expressions, although not all
forward-looking statements contain these identifying words.
Additional information concerning these and other factors that may
cause actual results to differ materially from those anticipated in
the forward-looking statements is contained in the "Risk Factors"
section of the Company's Annual Report on Form 10-K for the year
ended December 31, 2015, and in the Company's other periodic
reports and filings with the Securities and Exchange
Commission. The Company cautions investors not to place undue
reliance on the forward-looking statements contained in this press
release. All forward-looking statements are based on information
currently available to the Company on the date hereof, and the
Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this press release, except as required by
law.
Jack Howarth
Vice President, Corporate Affairs
609-359-3016
jhowarth@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jul 2023 to Jul 2024